Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group.
暂无分享,去创建一个
Katherine Payne | John Watkins | Jennifer Oberg | Susan R Snyder | Uwe Siebert | John B. Watkins | Maarten J IJzerman | Eric Faulkner | Anke-Peggy Holtorf | Surrey Walton | Christine Y Liu | Hwee Lin | Eman Biltaj | Diana Brixner | Charles Barr | Gurmit Shandhu | Simran Tiwana | U. Siebert | K. Payne | M. IJzerman | A. Holtorf | S. Tiwana | S. Walton | D. Brixner | Christine Y Liu | S. Snyder | E. Faulkner | Hwee Lin | Eman Biltaj | Charles Barr | Jennifer Oberg | Gurmit Shandhu | Charles Barr
[1] Katherine Payne,et al. Economic evaluations of personalized medicine: existing challenges and current developments , 2015, Pharmacogenomics and personalized medicine.
[2] S. Ou,et al. Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally? , 2014, Front. Oncol..
[3] Sean Khozin,et al. Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study. , 2018, Health affairs.
[4] Rae Woong Park,et al. Characterizing treatment pathways at scale using the OHDSI network , 2016, Proceedings of the National Academy of Sciences.
[5] A. Holtorf,et al. Patient Preference Studies During Early Drug Development: Aligning Stakeholders to Ensure Development Plans Meet Patient Needs , 2019, Front. Med..
[6] W. Rogowski,et al. What is personalized medicine: sharpening a vague term based on a systematic literature review , 2013, BMC Medical Ethics.
[7] Mark Nuijten,et al. Stratified Medicine and Reimbursement Issues , 2012, Front. Pharmacol..
[8] Katherine Payne,et al. Fish and chips all round? Regulation of DNA-based genetic diagnostics. , 2009, Health economics.
[9] K. Payne,et al. Current methodological issues in the economic assessment of personalized medicine. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[10] M. Ringo,et al. Are Global Health Systems Ready for Transformative Therapies? , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[11] Katherine Payne,et al. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[12] M. Piccart,et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] T. Lieu,et al. Evaluating Frameworks That Provide Value Measures for Health Care Interventions. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[14] Scott D Ramsey,et al. Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6]. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[15] S. Daack-Hirsch,et al. The role of patient engagement in personalized healthcare. , 2014, Personalized medicine.
[16] Uwe Siebert,et al. Personalized medicine in Europe: not yet personal enough? , 2017, BMC Health Services Research.
[17] Adam P Dicker,et al. American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] A. Clarke,et al. Communication of Information about Genetic Risks: Putting Families at the Center. , 2018, Family process.
[19] Estela S Estape,et al. Translation in Data Mining to Advance Personalized Medicine for Health Equity. , 2016, Intelligent information management.
[20] A. Barratt,et al. Evidence Based Medicine and Shared Decision Making: the challenge of getting both evidence and preferences into health care. , 2008, Patient education and counseling.
[21] Mark R. Trusheim,et al. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers , 2007, Nature Reviews Drug Discovery.
[22] Louis P Garrison,et al. An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2]. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[23] Yusuke Nakamura,et al. Pharmacogenomics and Patient Care: One Size Does Not Fit All , 2012, Science Translational Medicine.
[24] S. Astley,et al. Evaluation of a Stratified National Breast Screening Program in the United Kingdom: An Early Model-Based Cost-Effectiveness Analysis. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[25] V. Zah,et al. Health Technology Assessment for Molecular Diagnostics: Practices, Challenges, and Recommendations from the Medical Devices and Diagnostics Special Interest Group. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[26] Mark Kroese,et al. 'Personalized medicine': what's in a name? , 2014, Personalized medicine.
[27] B. Knoppers,et al. Personalized medicine and access to health care: potential for inequitable access? , 2012, European Journal of Human Genetics.
[28] M. Ignatiadis,et al. Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine. , 2019, Cancer research.
[29] Louis P Garrison,et al. Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3]. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[30] Oguzhan Alagoz,et al. Concepts of ‘Personalization’ in Personalized Medicine: Implications for Economic Evaluation , 2014, PharmacoEconomics.
[31] I. Budin-Ljøsne,et al. Patient and interest organizations’ views on personalized medicine: a qualitative study , 2016, BMC Medical Ethics.
[32] A. Butte,et al. Disease Risk Factors Identified Through Shared Genetic Architecture and Electronic Medical Records , 2014, Science Translational Medicine.
[33] Deirdre Mladsi,et al. The faces of personalized medicine: a framework for understanding its meaning and scope. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[34] Martin Eden,et al. Toward health technology assessment of whole-genome sequencing diagnostic tests: challenges and solutions. , 2017, Personalized medicine.
[35] Bertalan Meskó,et al. The role of artificial intelligence in precision medicine , 2017 .
[36] A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics , 2016, Front. Genet..
[37] Randy Burkholder,et al. ISPOR's Initiative on US Value Assessment Frameworks: An Industry Perspective. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[38] Hannah Wood,et al. The Future of Precision Medicine: Potential Impacts for Health Technology Assessment , 2018, PharmacoEconomics.
[39] P. Neumann,et al. Three Sets of Case Studies Suggest Logic and Consistency Challenges with Value Frameworks. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[40] P. Williams-Russo,et al. The case for more active policy attention to health promotion. , 2002, Health affairs.
[41] Hendrik Koffijberg,et al. A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models , 2017, Expert review of pharmacoeconomics & outcomes research.
[42] C. Marzuillo,et al. How is genetic testing evaluated? A systematic review of the literature , 2018, European Journal of Human Genetics.
[43] Robert M. Plenge,et al. Disciplined approach to drug discovery and early development , 2016, Science Translational Medicine.
[44] K. Facey,et al. Putting Patients at the Centre of Healthcare: Progress and Challenges for Health Technology Assessments , 2018, The Patient - Patient-Centered Outcomes Research.
[45] Y. Vergouwe,et al. Validation, updating and impact of clinical prediction rules: a review. , 2008, Journal of clinical epidemiology.
[46] P. Froguel,et al. Translational research: precision medicine, personalized medicine, targeted therapies: marketing or science? , 2015, Therapie.
[47] Josh J. Carlson,et al. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis , 2013, Breast Cancer Research and Treatment.
[48] Virginia G Kaklamani,et al. Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer , 2018, The New England journal of medicine.
[49] E. Pearson. Personalized medicine in diabetes: the role of ‘omics’ and biomarkers , 2016, Diabetic medicine : a journal of the British Diabetic Association.
[50] B. Larijani,et al. Ethical Issues Surrounding Personalized Medicine: A Literature Review. , 2017, Acta medica Iranica.
[51] Maarten J. IJzerman,et al. Health economic impact of liquid biopsies in cancer management , 2018, Expert review of pharmacoeconomics & outcomes research.
[52] B. Knoppers,et al. The ethical framing of personalized medicine , 2014, Current opinion in allergy and clinical immunology.
[53] K. Payne,et al. Identification of factors that may influence the selection of first‐line biological therapy for people with psoriasis: a prospective, multicentre cohort study , 2017, The British journal of dermatology.
[54] D. Mott. Incorporating Quantitative Patient Preference Data into Healthcare Decision Making Processes: Is HTA Falling Behind? , 2018, The Patient - Patient-Centered Outcomes Research.
[55] R. Green,et al. Assessing the Costs and Cost-Effectiveness of Genomic Sequencing , 2015, Journal of personalized medicine.
[56] K. Kinzler,et al. Applications of liquid biopsies for cancer , 2019, Science Translational Medicine.
[57] Yann Joly,et al. Integrating precision cancer medicine into healthcare—policy, practice, and research challenges , 2016, Genome Medicine.